These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28934761)

  • 61. Is the pathological regression level of metastatic lymph nodes associated with oncologic outcomes following preoperative chemoradiotherapy in rectal cancer?
    Choi JP; Kim SJ; Park IJ; Hong SM; Lee JL; Yoon YS; Kim CW; Lim SB; Lee JB; Yu CS; Kim JC
    Oncotarget; 2017 Feb; 8(6):10375-10384. PubMed ID: 28060748
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
    Lindebjerg J; Spindler KL; Ploen J; Jakobsen A
    Colorectal Dis; 2009 Mar; 11(3):264-9. PubMed ID: 18573119
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Can tumor regression grade influence survival outcome in ypT3 rectal cancer?
    Shen L; Wang L; Li G; Zhang H; Liang L; Fan M; Wu Y; Deng W; Sheng W; Zhu J; Zhang Z
    Clin Transl Oncol; 2016 Jul; 18(7):693-9. PubMed ID: 26527031
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer.
    Suárez J; Vera R; Balén E; Gómez M; Arias F; Lera JM; Herrera J; Zazpe C
    Colorectal Dis; 2008 Jul; 10(6):563-8. PubMed ID: 18070184
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Predictive value of modified MRI-based split scar sign (mrSSS) score for pathological complete response after neoadjuvant chemoradiotherapy for patients with rectal cancer.
    Yuan Y; Zheng K; Zhou L; Chen F; Zhang S; Lu H; Lu J; Shao C; Meng R; Zhang W; Gao X; Shen F
    Int J Colorectal Dis; 2023 Feb; 38(1):40. PubMed ID: 36790595
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
    Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer].
    Shu Z; Fang S; Ding Z; Mao D; Pang P; Gong X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1051-1058. PubMed ID: 30269327
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 69. MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.
    Seierstad T; Hole KH; Grøholt KK; Dueland S; Ree AH; Flatmark K; Redalen KR
    Br J Radiol; 2015 Jul; 88(1051):20150097. PubMed ID: 25899892
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Profiling of rectal cancers MRI in pathological complete remission states after neoadjuvant concurrent chemoradiation therapy.
    Kim H; Kim HM; Koom WS; Kim NK; Kim MJ; Kim H; Hur H; Lim JS
    Clin Radiol; 2016 Mar; 71(3):250-7. PubMed ID: 26747329
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Validation of the standardized index of shape tool to analyze DCE-MRI data in the assessment of neo-adjuvant therapy in locally advanced rectal cancer.
    Fusco R; Granata V; Sansone M; Rega D; Delrio P; Tatangelo F; Romano C; Avallone A; Pupo D; Giordano M; Grassi R; Ravo V; Pecori B; Petrillo A
    Radiol Med; 2021 Aug; 126(8):1044-1054. PubMed ID: 34041663
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rectal cancer staging post neoadjuvant therapy--how should the changes be assessed?
    Bateman AC; Jaynes E; Bateman AR
    Histopathology; 2009 May; 54(6):713-21. PubMed ID: 19438746
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer.
    Huang MY; Lee HH; Tsai HL; Huang CW; Yeh YS; Ma CJ; Huang CM; Chen CY; Huang JJ; Wang JY
    Radiat Oncol; 2018 Mar; 13(1):53. PubMed ID: 29587797
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Neoadjuvant chemoradiotherapy for rectal cancer: how important is tumour regression?
    McCoy MJ; Hemmings C; Hillery S; Penter C; Bulsara MK; Zeps N; Platell CF
    ANZ J Surg; 2017 Dec; 87(12):E233-E239. PubMed ID: 26631340
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy.
    Baird DLH; Denost Q; Simillis C; Pellino G; Rasheed S; Kontovounisios C; Tekkis PP; Rullier E
    Colorectal Dis; 2017 Nov; 19(11):980-986. PubMed ID: 28493401
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Significance of Magnetic Resonance Imaging-Assessed Tumor Response for Locally Advanced Rectal Cancer Treated With Preoperative Long-Course Chemoradiation.
    Fayaz MS; Demian GA; Fathallah WM; Eissa HE; El-Sherify MS; Abozlouf S; George T; Samir SM
    J Glob Oncol; 2016 Aug; 2(4):216-221. PubMed ID: 28717704
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy.
    García VM; Batlle JF; Casado E; Burgos E; de Castro J; Belda C; Barriuso J; Sánchez JJ; García-Cabezas MÁ; González-Barón M; Cejas P
    Colorectal Dis; 2011 Sep; 13(9):989-98. PubMed ID: 20718834
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy.
    Zhang LN; Xiao W; OuYang PY; You K; Zeng ZF; Ding PR; Pan ZZ; Xu RH; Gao YH
    Tumour Biol; 2015 Sep; 36(10):8213-9. PubMed ID: 25994571
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
    Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S
    J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
    Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P
    Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.